August 30, 2016
In 2016 the U.S. Food and Drug Administration approved ERELZI (etanercept-szzs) for the treatment of adults with plaque psoriasis and psoriatic arthritis, among other diseases. It is a biosimilar to ENBREL (entanercept), a biologic that was first approved in 1998. [1]
ERELZI is given by injection. It is manufactured by Sandoz, a Swiss-German-based pharmaceutical company. [1]
